Find the Thesis HereKYTX / NASDAQ
Can One Miv-cel Infusion Sustain Function Without Chronic Immunotherapy in Refractory Stiff-Person Syndrome?
A published thesis testing whether the one-year signal in refractory stiff-person syndrome can become durable function without chronic immunotherapy in routine US care after an FDA decision.
PublishedUpdated October 23, 2026
Open thesis →KYSA-8 one-year recordCompany reported
Treated patients26Single-arm, open-label Phase 2
Walk-time change49%Median within-patient reduction at one year
Off chronic immunotherapy24/26At one year; two restarted IVIg
BLA completionQ4 2026Company target; FDA action date unknown
Source: corrected KYSA-8 one-year poster, presented October 21, 2026. The study is single-arm, the BLA is incomplete and no FDA action date has been announced.